Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

817
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
817
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroencephalogram Data-Based Analysis of Paroxysmal Slow Wave Events Patterns in Brain Pathologies.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Pesticide residues in bedroom dust: occurrence, determinants, and health risk assessment.

Environmental pollution (Barking, Essex : 1987)·2025
Same author

Temporal trends and predictors of gestational exposure to organophosphate ester flame retardants and plasticizers.

Environment international·2023
Same author

Neuro-psychiatric symptoms in directly and indirectly blast exposed civilian survivors of urban missile attacks.

BMC psychiatry·2023
Same author

Impact of COVID-19 on clinical outcomes of robotic inguinal hernia repair.

Hernia : the journal of hernias and abdominal wall surgery·2023
Same author

The potential role of microvascular pathology in the neurological manifestations of coronavirus infection.

Fluids and barriers of the CNS·2020

Related Experiment Video

Updated: Jan 19, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.4K

Levodopa-induced dyskinesia: clinical observations.

A Friedman

    Journal of Neurology
    |January 1, 1985
    PubMed
    Summary

    Early onset Parkinson's disease and bradykinesia predict levodopa-induced dyskinesia. Starting levodopa therapy promptly may reduce dyskinesia risk in Parkinson's patients.

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Parkinson's disease (PD) is a progressive neurodegenerative disorder.
    • Levodopa is a primary treatment for PD, but can induce motor complications like dyskinesia.
    • Understanding risk factors for levodopa-induced dyskinesia (LID) is crucial for optimizing PD management.

    Purpose of the Study:

    • To investigate correlations between patient characteristics and the incidence of levodopa-induced dyskinesias (LID) in Parkinson's disease patients.
    • To identify predictive factors for LID development during prolonged levodopa therapy.

    Main Methods:

    • A cohort of 144 patients with Parkinson's disease receiving long-term levodopa treatment was studied.
    • Data collected included age at disease onset, clinical PD subtype, symptom duration before levodopa, levodopa treatment duration, and concomitant medications.

    More Related Videos

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.3K
    MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
    16:57

    MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

    Published on: February 14, 2012

    26.9K

    Related Experiment Videos

    Last Updated: Jan 19, 2026

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
    05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    4.4K
    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.3K
    MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
    16:57

    MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

    Published on: February 14, 2012

    26.9K
  • Incidence of LID was recorded and statistically analyzed against patient and treatment variables.

    • Main Results:

    • Levodopa-induced dyskinesia (LID) was observed in 64% of patients.
    • Significantly younger age at disease onset (mean 54.8 years) was associated with higher LID incidence compared to later onset (mean 68.9 years).
    • Patients with predominant bradykinesia showed higher LID rates (69%) than those with tremor (29%). Early initiation of levodopa therapy correlated with lower LID susceptibility.

    Conclusions:

    • Younger age at onset and bradykinetic PD subtype are significant risk factors for developing levodopa-induced dyskinesias.
    • Initiating levodopa therapy earlier in the disease course may mitigate the risk of dyskinesia.
    • Further research into biochemical mechanisms and clinical implications is warranted.